Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first
Global biotech firms are increasingly being drawn to Hong Kong for its growing investor base and proximity to Chinese pharmaceutical partners.
Record details
Published: 22 July 2026
Source: CNBC Technology
Category: News
Topics: Finance, VC & PE · Biotech
Retrieved: 22 July 2026
Related evidence
These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.
Investors bet on AI drug discovery despite approval gap
Financial Times Technology (headlines) · 21 July 2026
How AI helps scientists design the next generation of medicines
MIT Technology Review · 23 July 2026
Exclusive: A couple paid more than $800,000 for a gene-editing therapy for their daughter. She died, and it wasn’t made public
Retraction Watch · 23 July 2026
An OpenAI researcher is leaving to build a $2bn AI drug startup that has no name yet
The Next Web AI · 15 July 2026
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
TechCrunch · 15 July 2026
Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma
SiliconANGLE AI · 14 July 2026
How to cite this record
ethics.ai (22 July 2026), “Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first,” evidence record 12454, https://ethics.ai/record/12454 (originally published by CNBC Technology).
Use and limitations
This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.